16 June 2022

Will Authorised Biologics Deter Biosimilars Utilising JFTC's Expertise in Drug Pricing

In the US, the impact of authorised biologics on biosimilars is post-regulated by the competition authorities, while in Europe, pharmaceutical regulatory authorities consider competition impacts in addition to post-regulation by the competition authorities.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Novartis shields eye-drop patent at European Patent Office

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Will Authorised Biologics Deter Biosimilars Utilising JFTC's Expertise in Drug Pricing

Editor's picks

Editor's picks

More features